



Microbiome Characterization of Infected Diabetic Foot Ulcers in Association With Clinical Outcomes: Traditional Cultures Versus Molecular Sequencing Methods

OPEN ACCESS

Edited by:

José Luis Lázaro Martínez, Complutense University of Madrid, Spain

Reviewed by:

Vijay Viswanathan, Prof. M. Viswanathan Diabetes Research Center, India Esther García Morales, Universidad Complutense de Madrid, Spain

*Correspondence:

Naama Geva-Zatorsky naama_gz@technion.ac.il Hadar Mudrik-Zohar hadar.mudrik@gmail.com

[†]These authors have contributed equally to this work

[‡]These authors have contributed equally to this work

Specialty section:

This article was submitted to Microbiome in Health and Disease, a section of the journal Frontiers in Cellular and Infection Microbiology

> Received: 15 December 2021 Accepted: 01 March 2022 Published: 24 March 2022

Citation:

Mudrik-Zohar H, Carasso S, Gefen T, Zalmanovich A, Katzir M, Cohen Y, Paitan Y, Geva-Zatorsky N and Chowers M (2022) Microbiome Characterization of Infected Diabetic Foot Ulcers in Association With Clinical Outcomes: Traditional Cultures Versus Molecular Sequencing Methods. Front. Cell. Infect. Microbiol. 12:836699. doi: 10.3389/fcimb.2022.836699 Hadar Mudrik-Zohar^{1,2*†}, Shaqed Carasso^{3†}, Tal Gefen³, Anat Zalmanovich^{2,4}, Michal Katzir^{2,4}, Yael Cohen⁵, Yossi Paitan^{2,6}, Naama Geva-Zatorsky^{3,7*‡} and Michal Chowers^{2,4‡}

¹ Department of Internal Medicine A, Meir Medical Center, Kfar Saba, Israel, ² Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ³ Rappaport Technion Integrated Cancer Center (TICC), Department of Cell Biology and Cancer Science, Rappaport Faculty of Medicine, The Technion – Israel Institute of Technology, Haifa, Israel, ⁴ Infectious Diseases Unit, Meir Medical Center, Kfar Saba, Israel, ⁵ Department of Orthopedics B, Meir Medical Center, Kfar Saba, Israel, ⁶ Clinical Microbiology Laboratory, Meir Medical Center, Kfar Saba, Israel, ⁷ Canadian Institute for Advanced Research (CIFAR), Toronto, ON, Canada

Background: Infected diabetic foot ulcers (IDFU) are a major complication of diabetes mellitus. These potentially limb-threatening ulcers are challenging to treat due to impaired wound healing characterizing diabetic patients and the complex microbial environment of these ulcers.

Aim: To analyze the microbiome of IDFU in association with clinical outcomes.

Methods: Wound biopsies from IDFU were obtained from hospitalized patients and were analyzed using traditional microbiology cultures, 16S rRNA sequencing and metagenomic sequencing. Patients' characteristics, culture-based results and sequencing data were analyzed in association with clinical outcomes.

Results: A total of 31 patients were enrolled. Gram-negative bacteria dominated the IDFU samples (79%, 59% and 54% of metagenomics, 16S rRNA and cultures results, respectively, p<0.001). 16S rRNA and metagenomic sequencing detected significantly more anaerobic bacteria, as compared to conventional cultures (59% and 76%, respectively vs. 26% in cultures, p=0.001). Culture-based results showed that *Staphylococcus aureus* was more prevalent among patients who were treated conservatively (p=0.048). In metagenomic analysis, the *Bacteroides* genus was more prevalent among patients who underwent amputation (p<0.001). Analysis of metagenomic-based functional data showed that antibiotic resistance genes and genes related to biofilm production and to bacterial virulent factors were more prevalent in IDFU that resulted in amputation (p<0.001).

1

Conclusion: Sequencing tools uncover the complex biodiversity of IDFU and emphasize the high prevalence of anaerobes and Gram-negative bacteria in these ulcers. Furthermore, sequencing results highlight possible associations among certain genera, species, and bacterial functional genes to clinical outcomes.

Keywords: diabetic foot ulcer, microbiome, 16S rRNA, metagenomics, amputation

INTRODUCTION

Diabetic foot ulcers (DFU) develop in 25% of diabetic patients (Volmer Thole and Lobmann, 2016); half of which become infected (IDFU) and 68% cause osteomyelitis (Armstrong et al., 1998; Boulton et al., 2005; Lavery et al., 2006; Van Asten et al., 2016; Lavery et al., 2017). Approximately 12% of patients with IDFU require disabling lower limb amputation within five years of the initial foot lesion. These amputations cause functional deterioration and reduce quality of life (Armstrong et al., 1998; Volmer Thole and Lobmann, 2016).

The polymicrobial nature of the ulcers and the poor clinical response to long-term antibiotics, make IDFU challenging to treat (Hunt, 1992). Furthermore, it is complicated to differentiate culture-isolated causative pathogens from skin and environmental contaminants during acute exacerbation (Gardner et al., 2014). In some cases, it is not clear whether all isolated bacteria necessitate antibiotic treatment, especially when the sample is collected using superficial swabbing, rather than deep wound biopsies which are considered more reliable and therefore are recommended (Pellizzer et al., 2001; Treece et al., 2004; Lipsky et al., 2016; Lipsky et al., 2020). Lipsky et al. reported that patients with DFU with methicillin-resistant Staphylococcus aureus (MRSA) or Pseudomonas spp. Positive cultures exhibited good response to antibiotics that do not cover these organisms (Lipsky et al., 2005). This study also showed that Pseudomonas aeruginosa and Enterococcus spp. Colonized wounds without impairing wound healing (Lipsky et al., 2020). These findings reflect the limitations of cultures, that may reveal only partial results with respect to the diverse microbiota of the wounds (Dowd et al., 2008; Rhoads et al., 2012a; Rhoads et al., 2012b). Other well-known limitations of cultures are their selectivity to growth conditions and the risk of false-negative results due to prior antibiotic treatment (Kallstrom, 2014).

Improved diagnostic approaches are needed to decrease treatment failures, as the prevalence of diabetes mellitus is increasing worldwide, and consequently the number of patients dealing with diabetic foot ulcers is rising (Lavery et al., 2006). Molecular tools such as 16S rRNA and metagenomic sequencing provide detailed information about bacterial communities. However, data regarding the clinical implications of sequenced results from IDFU is scarce. Most published results to date focused on out-patients with uninfected ulcers and were limited in the taxonomic depth of analysis (Van Asten et al., 2016; Wolcott et al., 2016). Very few studies used metagenomic sequencing to obtain detailed mapping of the biodiversity of the ulcers, including functional genes (Suryaletha et al., 2018; Kalan et al., 2019). Here, we analyzed IDFU biopsies in hospitalized patients processed in parallel using cultures, 16S rRNA sequencing and metagenomics, and investigated microbial associations with clinical outcomes.

METHODS

Study Setting and Population

The study was conducted April through September 2019 at Meir Medical Center (Kfar-Saba, Israel), a secondary medical center with 66,000 admissions per year, serving a population of 600,000 individuals. Inclusion criteria were: (a) age>18 years old (b) established diagnosis of type 2 diabetes mellitus (c) hospitalization to the Department of Orthopedics with IDFU during study period. Patients who had surgical intervention in the affected foot one month before enrollment or exhibited signs of another acute infection during hospitalization were excluded. Patients were divided into two groups according to clinical outcome: (a) "Conservative treatment" group (considered as the favorable clinical outcome) - included patients who were treated by intravenous antibiotic treatment with bedside debridement as needed, with no need of amputation up to 90 days post-discharge (b) "Amputation" group (considered as adverse clinical outcome) - included patients who underwent surgical toe resection or below knee amputation (BKA) during hospitalization, or within 90 days post-discharge. The clinical criteria for surgery were one of the following: (a) ulcers with extensive involvement of necrotizing soft tissue with poor response to IV antibiotic treatment (b) systemic inflammatory symptoms with no other source of infection and no response to IV antibiotic treatment. (c) chronic osteomyelitis of proximal phalanges, especially in cases with progressive bone destruction.

Antibiotic therapy during hospitalization was given at the discretion of the treating physician, and in accordance with available cultures.

Data Collection

Clinical data: Demographics, co-morbidities, laboratory measures, radiology imaging results and antibiotics prescribed one month before enrollment and given during hospitalization were collected from electronic medical records of all participants (**Figure 1**). The infected diabetic foot ulcer of each patient was clinically evaluated by an orthopedic surgeon or an infectious diseases physician upon admission.



A uniform protocol was used, based on Texas and IWGDF/ IDSA classifications (Lavery et al., 1996; Lipsky et al., 2012; Lipsky et al., 2016; Lipsky et al., 2020), which included ulcer's location, size, clinical signs of cellulitis, abscess or osteomyelitis, systemic toxicity, vascular and neurologic status. Osteomyelitis was diagnosed using the well-known "probe-to-bone" clinical diagnostic tool, supported by X-ray findings.

Clinical outcomes measured: Length of stay (LOS), days of antibiotic therapy in-hospital, below knee or toe amputation (up to 90 days post discharge) and recurrent admissions.

Deep tissue biopsy collection: Biopsies were obtained by orthopedic surgeons after sterilization and debridement of superficial necrotic tissues. Two samples were collected from each participant: one for culture and the other for DNA extraction. The samples were collected simultaneously or no more than 48 hours apart.

Culture techniques: Biopsies were cultured in the microbiology Laboratory at Meir Medical Center. See **Supplementary Materials** for detailed culturing protocol.

DNA extraction and sequencing: Biopsies for DNA extraction were kept at -80°C within one hour after collection and were sent to the Geva-Zatorsky Laboratory, at the Technion Faculty of Medicine, Haifa, for extraction. Detailed extraction protocol is summarized in the **Supplementary Materials**. 16S rRNA and metagenomic sequencing were performed for each biopsy at the Sequencing Core at the University of Illinois at Chicago. For sequencing protocols, see **Supplementary Materials**.

Statistics and Bioinformatics

Data were presented as number and percentage for nominal variables and as mean or median for continuous data. Categorical variables were compared using the chi-square test or Fisher-Exact test. Continuous data were compared using the T-test or the Mann-Whitney-U test. Friedman-test for non-parametric related samples was used to find differences among the three methods. P<0.05 was considered statistically significant. Data were analysed using SPSS, version 25 (IBM Corp., Armonk, NY).

Taxonomic data were filtered for bacteria and subsequently filtered by a minimum of 0.1% relative abundance and detection in at least 3 samples. Description of the analysis methods and details regarding the availability of the raw sequenced data are provided in the **Supplementary Materials**.

Two levels of analysis in association with clinical outcomes were performed:

(a) Comparison between culture and 16S rRNA sequencing results (N=30)

(b) Comparison between culture, 16S rRNA and metagenomic sequencing results (N=13).

Ethics

The study was performed in accordance with the declaration of Helsinki and was approved by the Institutional Ethics Committee of Meir Medical Center (0143-18MMC). Patients provided signed informed consent.

RESULTS

Patients' Characteristics

During the six-month study period, a total of 62 wound samples were obtained from 31 patients who met the inclusion criteria.

The study population characteristics are outlined in **Table 1**. Mean age was 62 years and 81% were men. Mean glycosylated hemoglobin was 8.8% and 94% were diagnosed with osteomyelitis. Twenty-three individuals underwent amputation (toe resection in 19 patients and BKA in 4) during

TABLE 1 | Patient characteristics at enrolment and clinical outcomes measured.

	Characteristic	Total (N=31)	Amputation (N=23)	Conservative treatment (N=8)	P-value
Men, N (b) (b) 7 (87) 0.50 Forefoct Julins (number of tess involved), N (9)	Age, years, mean (± SD)	62 (± 13.3)	61 (± 12.9)	64 (± 15.2)	0.65
User location Forefort culores (number of toos involved), N (%) 1 too (number of toos involved), N (%) 25 (%) 1 (3) 1 (4 (77) 1 (13) 1 (6 (78) 7 (87) 3 - 10cm 1 (3) 1 (4) 0 (0) 1 (6 (78) 7 (88) 3 - 10cm 3 - 10cm 1 (6 (79) 5 (22) 1 (13) 1 (6 (79) 1 (14) 1 (6 (79) 1 (14) 1 (14) 0 (0) 0.54 2 (25) 0.44 Cationnyalitis (0M) 2 (94) 2 (10(1) 6 (75) 0.48 1 (3) 1 (4) 0 (0) 0.54 2 (80) 1 (46) 1 (146) 3 (37) 1 (40) 0 (40) 1 (40) 0	Men, N (%)	25 (81)	18 (78)	7 (87)	0.50
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Ulcer location				
1 los 26 (8) 18 (76) 7 (87) >1 los 5 (16) 4 (17) 1 (3) Windfort Ucors 1 (3) 1 (4) 0 (0) Com 26 (81) 18 (78) 7 (88) 3-10 cm 6 (19) 5 (22) 1 (13) Intection cincial evaluation, N (%) 26 (81) 18 (78) 2 (25) 0.24 Obtion/myelits (CM) 29 (94) 21 (91) 8 (100) 0.64 Abacess 1 (3) 1 (46) 0 (10) 0.74 X-ray positive for CML N (%) 21 (82) 15 (86) 6 (75) 0.41 Singe B 17 (54) 12 (25) 5 (16) 0.10 0.22 Fibrids 3 1 1 0 0.221 0.24 0.22 0.24<	Forefoot ulcers (number of toes involved), N (%)				0.34
5 1 loe 5 (16) 4 (17) 1 (13) Hardbort Jobers, N (%) 0.00 0.50 -3 Con 5 (19) 5 (22) 1 (13) Breating (11) 6 (19) 5 (22) 1 (13) Cellulis 1 (34) 1 (14) 6 (10) 0.54 Cataony Bits (DM) 29 (94) 21 (91) 8 (100) 0.54 Abaces 1 (3) 1 (4) 0 (0) 0.44 Abaces 1 (3) 1 (4) 0 (0) 0.44 Tesse classification 29 (94) 21 (91) 8 (100) 0.60 Stage B 17 (54) 12 (52) 5 (62) 0.70 Stage B 1 1 0 0.21 PEDIS 3 15 9 6 PEDIS 4 15 13 (4 28) 10 (4 2.8) 0.11 VEC (Wull 3 admission, men (+ SD) 12 (4 8.3) 13 (4 8.8) 7 (4 9.5) 0.31 Antibiotic prescriptions 12 (30) 13 (4 8.8) 10 (4 2.8) 0.4 Antibiotic prescriptions <td>1 toe</td> <td>25 (81)</td> <td>18 (78)</td> <td>7 (87)</td> <td></td>	1 toe	25 (81)	18 (78)	7 (87)	
Hindbort Johers 1 (3) 1 (4) 0 (0) -3Cm 25 (61) 18 (72) 7 (88) -3-10cm 6 (19) 5 (22) 1 (13) Intection clinical evaluation, N (%) 23 (42) 21 (97) 8 (100) 0.54 Celutitis 23 (42) 21 (97) 8 (100) 0.54 Arcap costs for CM, N (%) 21 (82) 5 (82) 6 (27) 0.48 Texas classification 29 (84) 21 (97) 8 (100) 0.00 Stage B 17 (54) 12 (82) 5 (82) 0.70 Stage B 15 (5 3 (7) 0.01 0.00 PEDIS 2 1 1 0 0.21 PEDIS 3 15 9 6.1 0.14 PEDIS 4 15 13 (1.4.8) 0.17 Aburn at admission (20), man (± SD) 3.28 3.27 3.47 0.054 Artibolic prescriptions 12 (4:9) 13 (1.62) 6 (75) 0.48 Artibolic prescriptions 12 (80) 10 (42) 2 (25)	>1 toe	5 (16)	4 (17)	1 (13)	
Uber size, N. (%) -5:00m 25 (61) 16 (72) 7.68) 3-100m 6.19 5 (22) 1 (13) Inection clinical evaluation, N. (%) 23 (42) 21 (91) 8 (100) 0.54 Abacess 1 (3) 1 (4) 0 (0) 0.74 Abacess 1 (3) 1 (4) 0 (0) 0.74 Abacess 1 (3) 1 (4) 0 (0) 0.74 Array positive for CM, N (%) 21 (82) 15 (82) 6 (62) 0.70 Stage B 17 (54) 12 (52) 5 (62) 0.70 Stage D 14 (45) 11 (1) 0 0.21 FEDIS 3 15 9 6 0 FEDIS 4 15 13 (± 4.8) 10 (± 2.8) 0.11 WBC (kUL) at atchnission, grid (± 1) 1.1.3 11.04 11.3 0.77 Aburn at admission (grid), mean (± SD) 1.2 (± 9.3) 13 (± 4.8) 10 (± 2.8) 0.11 WBC (kUL) at admission (grid), mean (± SD) 1.2 (± 9.3) 13 (± 6.9) 7 (± 9.5) <	Hindfoot ulcers	1 (3)	1 (4)	O (O)	
s-30cm 25 (8) 18 (78) 7 (88) 3-10cm 61(19) 5 (22) 11(13) Infection clinical evaluation, N (%) 29 (94) 21 (91) 8 (1000) 0.54 Outcomyetilis (M) 29 (94) 21 (91) 8 (1000) 0.54 Abaroses 1 (3) 1 (4) 0 (0) 0.74 Xray positive for OM, N (%) 21 (83) 15 (85) 6 (75) 0.48 Teasa classification 29 (93) 21 (91) 8 (100) 0.60 Stage B 17 (54) 12 (82) 5 (82) 0.70 Stage B 17 (54) 12 (82) 5 (82) 0.70 Stage B 15 9 6 PEDIS 2 1 1 0 0.01 PEDIS 3 15 9 6 2 0.11 Not (4, 2, 8) 0.11 WBC (U4.) at admission, mean (± SD) 12 (4 4.5) 13 (4 4.8) 10 (4 2.8) 0.11 WBC (U4.) at admission (r/U1. mean (± SD) 3.28 3.27 3.47 0.055	Ulcer size, N (%)				0.50
3-10cm 6 (19) 5 (22) 1 (13) Intercton clinical evolution, N(%) 29 (94) 21 (91) 8 (100) 0.54 Abscess 1 (3) 1 (4) 0 (0) 0.74 K-ray positive for OM, N(%) 21 (93) 1 (4) 0 (0) 0.74 K-ray positive for OM, N(%) 21 (93) 1 (4) 0 (0) 0.74 K-ray positive for OM, N(%) 21 (93) 1 (4) 0 (0) 0.74 K-ray positive for OM, N(%) 21 (93) 12 (191) 8 (100) 0.60 Stage D 14 (46) 11 (48) 3 (37) 0.021 FEDIS 3 15 9 6 0.021 FEDIS 4 15 13 2 0.14 1.38 0.77 Albotic exposure Minh 30 disp me admission. 13 (± 4.8) 17 (± 9.8) 0.14 4 4.38 0.77 Albotic exposure Winh 30 disp me admission. 3 (28 3.27 3.47 0.054 Antibotic prescriptions 12 (4.8) 10 (43) 2 (25) 0.57 Anaerob	<3cm	25 (81)	18 (78)	7 (88)	
Infection chincial evaluation, N (%) 28 (34) 11 (48) 2 (25) 0.24 Octomyellis (OM) 29 (34) 21 (91) 8 (100) 0.54 Abaceas 1 (3) 1 (4) 0 (0) 0.74 Aray positive for OM, N (%) 21 (68) 15 (62) 6 (75) 0.48 Texas classification 5 5 (62) 0.70 Stage D 14 (45) 11 (49) 3 (37) Grade 3 WGBF/IDSA System classification 29 (93) 21 (91) 8 (100) 0.60 FEDIS 2 1 1 0 0.21 FEDIS 4 15 13 2 0.11 VEC (WL) 4 admission, mean (± SD) 12 (± 9.3) 13 (± 8.9) 7 (± 9.5) 0.114 Hemoglobh at admission (g/dL), mean (± SD) 13.3 11.04 11.38 0.77 Antibiotic proscriptions 12 (39) 13 (± 8.9) 10 (± 2.8) 0.14 Hemoglobh at admission (g/dL), mean (± SD) 3.28 3.27 3.47 0.054 Antibiotic proscriptions 19 (61) 13 (56) <t< td=""><td>3-10cm</td><td>6 (19)</td><td>5 (22)</td><td>1 (13)</td><td></td></t<>	3-10cm	6 (19)	5 (22)	1 (13)	
Calcing 13 (42) 11 (48) 2 (25) 0.24 Cateory wills (OM) 29 (64) 21 (91) 8 (100) 0.54 Abscess 1 (3) 1 (4) 0 (0) 0.74 Xray positive for OM, N (%) 21 (68) 15 (65) 6 (75) 0.48 Stage B 17 (54) 12 (52) 5 (62) 0.70 Grade 3 WGDF/DSA System classification 29 (93) 21 (91) 8 (100) 0.60 PEDIS 2 1 1 0 0.20 PEDIS 3 15 9 6 0.02 PEDIS 4 15 13 2 0.11 1.3 0.12 (± 4.5) 0.12 (± 4.5) 0.11 WBC (WL) at admission, mean (± SD) 12 (± 4.5) 13 (± 4.8) 10 (± 2.8) 0.11 WBC (WL) at admission (x04L), mean (± SD) 3.28 3.27 3.47 0.054 Antibiotic prescriptions 12 (39) 10 (43) 2 (25) 0.57 Antibiotic prescriptions 12 (39) 10 (43) 2 (25) 0.43 Antibiotic	Infection clinical evaluation, N (%)				
Obteomyelits (OM) 29 (94) 21 (91) 8 (100) 0.54 Abaccess 1 (3) 1 (4) 0 (0) 0.74 X-ray positive for OM, N (%) 21 (88) 15 (65) 6 (75) 0.48 Texas classification 7 12 (52) 5 (62) 0.70 Stage B 17 (54) 12 (52) 5 (62) 0.70 Grade 3 WGDF/IDSA System classification 29 (93) 21 (91) 8 (100) 0.60 PEDIS 2 1 1 0 0.21 C-Bacetive protein (mg/L) at admission, mean (± SD) 12 (± 9.3) 13 (± 4.8) 10 (± 2.8) 0.11 WBC (k/UL) at admission (g/L), mean (± SD) 11.3 11.04 11.38 0.77 Antibiotic prescriptions 12 (83) 10 (43) 2 (25) 0.67 No exposure 19 (61) 13 (55) 6 (75) 0.43 Antibiotic prescriptions 12 (83) 10 (43) 2 (25) 0.67 No exposure 19 (61) 12 (52) 7 (88) 0.90 Previous to amputation, N	Cellulitis	13 (42)	11(48)	2 (25)	0.24
Abscess 1 (3) 1 (4) 0 (0) 0.74 Xray positive OM, N (%) 21 (88) 15 (65) 6 (75) 0.48 Texas classification 50 (20) 5 (62) 0.70 Stage D 14 (43) 11 (48) 3 (37) Grade 3 WGDF/IDSA System classification 29 (93) 21 (91) 8 (100) 0.60 PEDIS C 1 1 0 0.21 PEDIS 3 15 9 6 0.11 1 0 0.21 PEDIS 4 15 13 2 0.14 1.13 0.14 1.13 0.11 WGC (VLL) at admission, mean (± SD) 12 (± 9.3) 13 (± 8.9) 7 (± 9.5) 0.11 Were option (admission (g/L), mean (± SD) 1.23 1.0.4 11.38 0.77 Aburnin at admission (g/L), mean (± SD) 3.28 3.27 3.47 0.054 Altiotice proceiptions 19 (61) 13 (56) 6 (75) 0.43 Antibiotice proceiptions 12 (39) 10 (43) 2 (25) 0.57 Anaerobic coverage 9 (29) 7 (30) 2 (25) 0.57	Osteomyelitis (OM)	29 (94)	21 (91)	8 (100)	0.54
X-ray positive for OM, N(%) 21 (60) 15 (65) 6 (.75) 0.48 Texas classification 21 (445) 12 (52) 5 (62) 0.70 Stage D 14 (45) 11 (48) 3 (37) 6 (54) 2 (54) 14 (45) 11 (48) 3 (37) 7 (54) 2 (54) 14 (45) 11 (48) 3 (37) 7 (54) 2 (54) 15 1 1 0 0 0.21 PEDIS 3 1 1 1 0 0 0.21 PEDIS 3 15 9 6 6 (55) 12 (\pm 9.3) 15 9 6 0 (55) 12 (\pm 9.3) 13 (\pm 8.9) 7 (\pm 9.5) 0.11 WEG (<i>i</i> /U, 1) at admission, mean (\pm SD) 12 (\pm 9.3) 13 (\pm 8.9) 7 (\pm 9.5) 0.11 WEG (<i>i</i> /U, 1) at admission (<i>g</i> /CL), mean (\pm SD) 12 (\pm 9.3) 13 (\pm 8.9) 7 (\pm 9.5) 0.11 WEG (<i>i</i> /U, 1) at admission (<i>g</i> /CL), mean (\pm SD) 11.3 1.04 11.38 0.777 Abumin at admission (<i>g</i> /CL), mean (\pm SD) 11.3 1.04 11.38 0.777 Abumin at admission (<i>g</i> /CL), mean (\pm SD) 3.28 3.27 3.47 0.054 Antibiotic exposure within 30 days pre-admission, N (%) 0.6 (75) 0.43 Antibiotic prescriptions 12 (69) 10 (43) 2 (25) 0.57 Anaerobic coverage 9 (29) 7 (30) 2 (25) Previous to se amputation, N (%) 12 (39) 8 (35) 4 (60) 0.36 Co-morbidities, N (%) 12 (39) 8 (35) 4 (60) 0.36 Co-morbidities, N (%) 12 (39) 8 (35) 10 (43) 1 (12) 0.12 Neuropathy 30 (97) 23 (100) 7 (88) 0.80 Opylapidemia 19 (61) 12 (52) 7 (85) 0.09 Congetive heart failure 9 (29) 6 (26) 3 (36) 0.42 Stehemic heart disease 8 (26) 6 6 (26) 2 (25) 0.67 Paroxyanal atrial fibrillation 4 (13) 3 (13) 1 (12) 0.12 Neuropathy 0.00 0.00 0.00 Congetive heart failure 9 (29) 6 (26) 2 (25) 0.67 Paroxyanal atrial fibrillation 4 (13) 3 (13) 1 (12) 0.73 Genetorvascular disease 7 (23) 7 (30) 0 (0) 0.09 Congetive heart failure 3 (310) 1 (4) 2 (25) 0.16 Chronic koltructive pulmonary disease 3 (10) 1 (4) 2 (25) 0.16 Chronic koltructive pulmonary disease 3 (10) 1 (4) 2 (25) 0.16 Chronic koltructive pulmonary disease 3 (10) 1 (4) 2 (25) 0.16 Chronic koltructive pulmonary disease 3 (10) 1 (4) 2 (25) 0.16 Chronic koltructive pulmonary disease 3 (10) 1 (4) 2 (25) 0.16 Chronic koltructive pulmonary disease 3 (10) 1 (4) 2 (25) 0.16 Chronic koltructive pulmonary disease 3 (10) 1 (2) 0.12 0.12 Chronic koltructive pulmonary disease 3 (10) 1 (2) 0.12 0.12 Ch	Abscess	1 (3)	1 (4)	O (O)	0.74
Texas classification 25 lage B 17 (54) 12 (52) 5 (62) 0.70 Stage D 14 (45) 11 (48) 3 (37) 0 Grade 3 MKDF/IDSA System classification 29 (93) 21 (91) 8 (100) 0.60 PEDIS 2 1 1 0 0.21 PEDIS 3 15 9 6 C-Reactive protein (mg/L) at admission, mean (± SD) 12 (± 4.5) 13 (± 8.9) 7 (± 9.5) 0.11 WBC (ivLu) at admission (g/GL), mean (± SD) 12 (± 4.5) 13 (± 8.9) 10 (± 2.8) 0.14 Henoglobin at admission (g/GL), mean (± SD) 3.28 3.27 3.47 0.054 Antibiotic presorupe within 30 days pre-admission, N (%) 13 (56) 6 (75) 0.43 Ne exposure 19 (61) 13 (56) 6 (75) 0.43 Antibiotic presoruptons 12 (39) 10 (43) 2 (25) 0.57 Anaetobic coverage 9 (29) 7 (30) 2 (25) 0.57 Anaetobic coverage 9 (29) 6 (25) 3 (35) 0.48 0.99 Cornothiditiss, N (%) 12 (59) 5 (25) 7 (88)	X-ray positive for OM, N (%)	21 (68)	15 (65)	6 (75)	0.48
Stage D 17 (64) 12 (62) 5 (62) 0.70 Stage D 14 (45) 11 (46) 3 (67) 0 Grade 3 IMGDF/IDSA System classification 29 (93) 21 (91) 8 (100) 0.60 PEDIS 3 15 9 6 0 0 0.21 PEDIS 4 15 13 2 0 0.14 0 0.21 C-Reactive portein (mg/L) at admission, mean (± SD) 12 (± 9.3) 13 (± 8.9) 7 (± 9.5) 0.11 WBUR (k/uL) at admission (g/dL), mean (± SD) 12 (± 9.3) 13 (± 4.8) 10 (± 2.8) 0.14 Hemoglobin at admission (g/dL), mean (± SD) 3.28 3.27 3.47 0.054 Antibiotic exposure with 30 days pre-admission, N (%) 12 (39) 10 (43) 2 (25) 0.57 Antibiotic prescriptions 12 (39) 10 (43) 2 (26) 0.57 Antibiotic prescriptions 12 (39) 10 (43) 1 (12) 0.12 Previous tee amputation, N (%) 12 (19) 8 (35) 4 (50) 0.36 Co-morbiditit	Texas classification				
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Stage B	17 (54)	12 (52)	5 (62)	0.70
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Stage D	14 (45)	11(48)	3 (37)	
PEDIS 2 1 1 0 0.21 PEDIS 3 15 9 6 7 7 9.5 13 2 C-Reactive protein (mg/L) at admission, mean (± SD) 12 (± 4.5) 13 (± 4.8) 7 (± 9.5) 0.11 WBC (i/U.L) at admission, mean (± SD) 11.3 11.04 11.38 0.77 Albumin at admission (g/dL), mean (± SD) 3.28 3.27 3.47 0.054 Albubic exposure within 30 days pre-admission, N (%) 12 (59) 10 (42.3) 0.41 Antibiotic exportings 12 (59) 8 (55) 4 (60) 0.33 Antibiotic exportings 12 (59) 8 (55) 4 (60) 0.36 Co-morbidities, N (%) 12 (59) 8 (55) 4 (60) 0.48 Peripheral vascular disease ^a 11 (35) 10 (43) 1 (12) 0.12 Neuropatify 30 (97) 22 (100) 7 (88) 0.09 0.48 Peripheral vascular disease 8 (26) 6 (26) 3 (38) 0.42 0.42 0.67 0.48 0.49 <t< td=""><td>Grade 3 IWGDF/IDSA System classification</td><td>29 (93)</td><td>21 (91)</td><td>8 (100)</td><td>0.60</td></t<>	Grade 3 IWGDF/IDSA System classification	29 (93)	21 (91)	8 (100)	0.60
PEDIS 3 15 9 6 PEDIS 4 15 13 2 C-Reactive protein (mg/L) at admission, mean (± SD) 12 (± 4.5) 13 (± 8.9) 7 (± 9.5) 0.11 WBC (MuL) at admission, mean (± SD) 12 (± 4.5) 13 (± 8.9) 10 (± 2.8) 0.14 Hemoglobin at admission (g/dL), mean (± SD) 3.28 3.27 3.47 0.054 Antibiotic exposure within 30 days pre-admission, N (%) 0 13 (± 6.8) 6 (7.5) 0.43 No exposure 9 (29) 7 (30) 2 (25) 0.57 Anatolicic expany 9 (29) 7 (30) 2 (25) 0.57 Previous to amputation, N (%) 12 (59) 8 (55) 4 (50) 0.36 Co-mortidities, N (%) 12 (59) 15 (65) 6 (7.5) 0.48 0.09 Dyslipidemia 21 (68) 15 (65) 6 (75) 0.48 0.69 Co-mortidities, N (%) 21 (52) 7 (83) 0.09 0.09 0.09 0.09 0.09 0.09 0.00 0.48 0.69 0.6	PEDIS 2	1	1	0	0.21
PEDS 415132C-Reactive protein (mg/L) at admission, mean (\pm SD)12 (\pm 4.5)13 (\pm 4.9)7 (\pm 9.5)0.11WBC (k/LL) at admission, mean (\pm SD)12 (\pm 4.5)13 (\pm 4.8)10 (\pm 2.8)0.14Hemoglobin at admission (g/dL), mean (\pm SD)3.283.273.470.054Atbibitic exposure within 30 days pre-admission, N (%)11.311.0411.380.77Ne exposure19 (61)13 (56)6 (75)0.43Artibitic prescriptions12 (39)10 (43)2 (25)0.57Anaerobic coverage9 (22)7 (30)2 (25)0.56Previous to a amputation, N (%)12 (39)8 (35)4 (50)0.36Co-morbidities, N (%)13 (\pm 4.1510 (43)1 (12)0.12Neuropathy30 (97)23 (100)7 (88)0.80Dysliptionia19 (61)12 (52)7 (86)0.09Congestive heart failure9 (29)6 (26)2 (25)0.67Paroxysmal atrial fibrillation4 (13)3 (13)1 (12)0.73Chronic obstructive pulmonary disease3 (10)1 (4)0 (0)0.74Smoker7 (23)5 (22)2 (25)0.67Paroxysmal atrial fibrillation4 (13)3 (13)1 (12)0.72Chronic obstructive pulmonary disease1 (3)1 (4)0 (0)0.74Smoker7 (23)5 (22)2 (25)0.65Past smoker3 (10)2 (8)1 (10)4.45 <tr< td=""><td>PEDIS 3</td><td>15</td><td>9</td><td>6</td><td></td></tr<>	PEDIS 3	15	9	6	
$\begin{array}{cccccc} C-Reactive protein (mg/L) at admission, mean (\pm SD) & 12 (\pm 4.5) & 13 (\pm 4.8) & 10 (\pm 2.8) & 0.11 \\ WBC (k/uL) at admission (g/dL), mean (\pm SD) & 11.3 & 11.04 & 11.38 & 0.77 \\ Albumin at admission (g/dL), mean (\pm SD) & 3.28 & 3.27 & 3.47 & 0.054 \\ Antibiotic exposure within 30 days pre-admission, N (%) & & & & & & & & & & & & & & & & & & &$	PEDIS 4	15	13	2	
$\begin{array}{cccc} WBC (k/uL) at admission, mean (\pm SD) & 12 (\pm 4.5) & 13 (\pm 4.8) & 10 (\pm 2.8) & 0.14 \\ \mbox{Hermoschipsion (g/uL), mean (\pm SD) & 3.28 & 3.27 & 3.47 & 0.054 \\ \mbox{Antibiotic exposure within 30 days pre-admission, N (%) & & & & & & & & & & & & & & & & & & &$	C-Reactive protein (mg/L) at admission, mean (± SD)	12 (± 9.3)	13 (± 8.9)	7 (± 9.5)	0.11
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	WBC (k/uL) at admission, mean (± SD)	12 (± 4.5)	13 (±4.8)	10 (± 2.8)	0.14
Albumin at admission (g/dL), mean (± SD) 3.28 3.27 3.47 0.054 Antibiotic exposure within 30 days pre-admission, N (%) 19 (61) 13 (56) 6 (75) 0.43 Antibiotic prescriptions 12 (39) 10 (43) 2 (25) 0.57 Anaerobic coverage 9 (29) 7 (30) 2 (25) 0.57 Previous te amputation, N (%) 12 (39) 8 (35) 4 (50) 0.36 Co-morbidities, N (%) 12 (39) 8 (35) 6 (75) 0.48 Peripheral vascular disease ^a 11 (35) 10 (43) 11 (2) 0.12 Neuropathy 30 (97) 23 (100) 7 (88) 0.80 Dyslipidemia 19 (61) 12 (52) 7 (88) 0.42 Ischeric heart disease 8 (26) 6 (26) 3 (38) 0.42 Ischeric kiney disease 7 (23) 7 (30) 0 (0) 0.09 Chronic obstructive pulmonary disease 1 (3) 1 (4) 0 (0) 0.74 Smoking T 2 (3) 5 (22) 2 (25) 0.45 Past smoker 3 (10) 1 (4) 0 (0) 0.74	Hemoglobin at admission (g/dL), mean (\pm SD)	11.3	11.04	11.38	0.77
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	Albumin at admission (g/dL), mean (± SD)	3.28	3.27	3.47	0.054
No exposure 19 (61) 13 (66) 6 (75) 0.43 Antibiotic prescriptions 12 (39) 10 (43) 2 (25) 0.57 Anaerobic coverage 9 (29) 7 (30) 2 (25) 0.36 Previous tee amputation, N (%) 12 (39) 8 (35) 4 (50) 0.36 Co-mothidities, N (%) 12 (38) 15 (65) 6 (75) 0.43 Peripheral vascular disease ^a 11 (35) 10 (43) 1 (12) 0.12 Neuropathy 30 (97) 23 (100) 7 (88) 0.80 Dyslipidemia 19 (61) 12 (52) 7 (88) 0.09 Congestive heart disease 8 (26) 6 (26) 2 (25) 0.67 Paroxysmal atrial fibrillation 4 (13) 3 (13) 1 (12) 0.73 Cerborovascular disease 7 (23) 7 (30) 0 (0) 0.09 Chronic kidney disease 3 (10) 1 (4) 0 (0) 0.74 Smoker 7 (23) 5 (22) 2 (25) 0.16 Chronic kidney disease 3 (10) </td <td>Antibiotic exposure within 30 days pre-admission, N (%)</td> <td></td> <td></td> <td></td> <td></td>	Antibiotic exposure within 30 days pre-admission, N (%)				
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	No exposure	19 (61)	13 (56)	6 (75)	0.43
Anaerobic coverage 9 (29) 7 (30) 2 (25) Previous toe amputation, N (%) 12 (39) 8 (35) 4 (50) 0.36 Co-motibidities, N (%) 21 (68) 15 (65) 6 (75) 0.48 Peripheral vascular disease ^a 11 (35) 10 (43) 1 (12) 0.12 Neuropathy 30 (97) 23 (100) 7 (88) 0.80 Dyslipidemia 19 (61) 12 (52) 7 (88) 0.09 Congestive heart failure 9 (29) 6 (26) 2 (25) 0.67 Paroxysmal atrial fibrillation 4 (13) 3 (13) 1 (12) 0.73 Cerebrovascular disease 7 (23) 7 (30) 0 (0) 0.09 Chronic kidney disease 1 (3) 1 (4) 0 (0) 0.74 Smoking 3 (10) 2 (9) 0 (42) 0.72 Recent glycosylated hemoglobin, mean (± SD) 8.8 (± 2) 8.8 (± 2) 9.0 (± 2) 0.72 Or-3 6 (19) 5 (24) 1 (10) 4.5 6 (19) 4 (17)	Antibiotic prescriptions	12 (39)	10 (43)	2 (25)	0.57
Previous toe amputation, N (%) 12 (39) 8 (35) 4 (50) 0.36 Co-morbidities, N (%)	Anaerobic coverage	9 (29)	7 (30)	2 (25)	
$\begin{array}{c c c c c c c } \hline Co-morbidities, N (%) \\ \hline Esential hypertension & 21 (68) & 15 (65) & 6 (75) & 0.48 \\ \hline Peripheral vascular disease^a & 11 (35) & 10 (43) & 1 (12) & 0.12 \\ \hline Neuropathy & 30 (97) & 23 (100) & 7 (88) & 0.09 \\ \hline Oxgestive heart failure & 9 (29) & 6 (26) & 3 (38) & 0.42 \\ Ischemic heart disease & 8 (26) & 6 (26) & 2 (25) & 0.67 \\ \hline Paroxysmal atrial fibrillation & 4 (13) & 3 (13) & 1 (12) & 0.73 \\ \hline Oxrop oxysma atrial fibrillation & 4 (13) & 3 (13) & 1 (12) & 0.73 \\ \hline Oxrop oxysma atrial isease & 7 (23) & 7 (30) & 0 (0) & 0.09 \\ \hline Ohronic kidney disease & 3 (10) & 1 (4) & 2 (25) & 0.16 \\ \hline Ohronic obstructive pulmonary disease & 3 (10) & 1 (4) & 0 (0) & 0.74 \\ \hline Smoking & & & & & & & & & & & & & & & & & & &$	Previous toe amputation, N (%)	12 (39)	8 (35)	4 (50)	0.36
Essential hypertension 21 (68) 15 (65) 6 (75) 0.48 Peripheral vascular disease ⁿ 11 (35) 10 (43) 1 (12) 0.12 Neuropathy 30 (97) 23 (100) 7 (88) 0.80 Dyslipidemia 19 (61) 12 (52) 7 (88) 0.60 Congestive heart failure 9 (29) 6 (26) 2 (25) 0.67 Paroxysmal atrial fibrillation 4 (13) 3 (13) 1 (12) 0.73 Chronic kidney disease 7 (23) 7 (30) 0 (0) 0.09 Chronic kidney disease 1 (3) 1 (4) 2 (25) 0.67 Paroxysmal atrial fibrillation 4 (13) 3 (10) 0 (0) 0.09 Chronic kidney disease 1 (3) 1 (4) 0 (0) 0.74 Smoking	Co-morbidities, N (%)				
Peripheral vascular disease ^a 11 (35) 10 (43) 1 (12) 0.12 Neuropathy 30 (97) 23 (100) 7 (88) 0.80 Dyslipidemia 19 (61) 12 (52) 7 (88) 0.99 Congestive heart failure 9 (29) 6 (26) 3 (38) 0.42 Ischemic heart disease 8 (26) 6 (26) 2 (25) 0.67 Paroxysmal atrial fibrillation 4 (13) 3 (13) 1 (12) 0.73 Cerebrovascular disease 7 (23) 7 (30) 0 (0) 0.09 Chronic kidney disease 3 (10) 1 (4) 0 (0) 0.74 Smoking	Essential hypertension	21 (68)	15 (65)	6 (75)	0.48
Neuropathy 30 (97) 23 (100) 7 (88) 0.80 Dyslipidemia 19 (61) 12 (52) 7 (88) 0.09 Congestive heart failure 9 (29) 6 (26) 3 (38) 0.42 Ischemic heart disease 8 (26) 6 (26) 2 (25) 0.67 Paroxysmal atrial fibrillation 4 (13) 3 (13) 1 (12) 0.73 Cerebrovascular disease 7 (23) 7 (30) 0 (0) 0.09 Chronic kidney disease 3 (10) 1 (4) 2 (25) 0.16 Chronic obstructive pulmonary disease 1 (3) 1 (4) 0 (0) 0.74 Smoking 3 (10) 2 (9) 1 (12) 0.45 Past smoker 7 (23) 5 (22) 2 (25) 0.45 0.45 Past smoker 3 (10) 2 (9) 1 (12) 0.45 Past smoker 6 (19) 4 (17) 2 (25) 0.5 O-3 6 (19) 4 (17) 2 (25) >6 0-3 6 (19) <td< td=""><td>Peripheral vascular disease^a</td><td>11 (35)</td><td>10 (43)</td><td>1 (12)</td><td>0.12</td></td<>	Peripheral vascular disease ^a	11 (35)	10 (43)	1 (12)	0.12
Dyslipidemia 19 (61) 12 (52) 7 (88) 0.09 Congestive heart failure 9 (29) 6 (26) 3 (38) 0.42 Ischemic heart disease 8 (26) 6 (26) 2 (25) 0.67 Paroxysmal atrial fibrillation 4 (13) 3 (13) 1 (12) 0.73 Cerebrovascular disease 7 (23) 7 (30) 0 (0) 0.09 Chronic kidney disease 3 (10) 1 (4) 2 (25) 0.16 Chronic kidney disease 3 (10) 1 (4) 0 (0) 0.74 Smoker 7 (23) 5 (22) 2 (25) 0.45 Past smoker 3 (10) 2 (9) 1 (12) 0.45 Recent glycosylated hemoglobin, mean (± SD) 8.8 (± 2) 8.8 (± 2) 9.0 (± 2) 0.72 Charlson Comorbidity Index ^b N (%) 0.3 6 (19) 4 (17) 2 (25) 0.45 >6 19 (61) 12 (52) 7 (88) 0.54 0.56 0.52 0.56 0.52 0.51 >6 19 (61) <	Neuropathy	30 (97)	23 (100)	7 (88)	0.80
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Dyslipidemia	19 (61)	12 (52)	7 (88)	0.09
Ischemic heart disease 8 (26) 6 (26) 2 (25) 0.67 Paroxysmal atrial fibrillation 4 (13) 3 (13) 1 (12) 0.73 Cerebrovascular disease 7 (23) 7 (30) 0 (0) 0.09 Chronic kidney disease 3 (10) 1 (4) 2 (25) 0.16 Chronic obstructive pulmonary disease 1 (3) 1 (4) 0 (0) 0.74 Smoking 5 (22) 2 (25) 0.45 Past smoker 7 (23) 5 (22) 2 (25) 0.45 Past smoker 3 (10) 2 (9) 1 (12) 0.45 Recent glycosylated hemoglobin, mean (± SD) 8 (8 (± 2) 8.8 (± 2) 9.0 (± 2) 0.72 Charlson Comorbidity Index ^b N (%) 0.4 (17) 2 (25) 0.8 0-3 6 (19) 5 (24) 1 (10) 4.75 5 (88) 0.9 0.31 0utcomes measured 12 (52) 7 (88) 0.31 0.31 0.31 0.31 0.31 0.54	Congestive heart failure	9 (29)	6 (26)	3 (38)	0.42
Paroxysmal atrial fibrillation 4 (13) 3 (13) 1 (12) 0.73 Cerebrovascular disease 7 (23) 7 (30) 0 (0) 0.09 Chronic kidney disease 3 (10) 1 (4) 2 (25) 0.16 Chronic obstructive pulmonary disease 1 (3) 1 (4) 0 (0) 0.74 Smoking 7 5 (22) 2 (25) 0.45 Past smoker 7 (23) 5 (22) 2 (25) 0.45 Past smoker 3 (10) 2 (9) 1 (12) 0.45 Recent glycosylated hemoglobin, mean (± SD) 8 (± 2) 8.8 (± 2) 9.0 (± 2) 0.72 Charlson Comorbidity Index ^b N (%) 0 0.16 0.45 0.8 0.6 0.8 0.10 0.8 0.72 0.72 O-3 6 (19) 5 (24) 1 (10) 0.8 0.72 0.8 0.8 0.9 0.16 0.8 0.9 0.72 0.8 0.8 0.9 0.16 0.9 0.17 0.8 0.8 0.10 0.9 0.31	Ischemic heart disease	8 (26)	6 (26)	2 (25)	0.67
$\begin{array}{c c} \mbox{Cerebrovascular disease} & 7 (23) & 7 (30) & 0 (0) & 0.09 \\ \mbox{Chronic kidney disease} & 3 (10) & 1 (4) & 2 (25) & 0.16 \\ \mbox{Chronic obstructive pulmonary disease} & 1 (3) & 1 (4) & 0 (0) & 0.74 \\ \mbox{Smoking} & & & & & & & & & \\ \mbox{Smoker} & 7 (23) & 5 (22) & 2 (25) & 0.45 \\ \mbox{Past smoker} & 3 (10) & 2 (9) & 1 (12) & 0.45 \\ \mbox{Past smoker} & 3 (10) & 2 (9) & 1 (12) & 0.45 \\ Recent glycosylated hemoglobin, mean (\pm SD) & 8.8 (\pm2) & 8.8 (\pm2) & 9.0 (\pm2) & 0.72 \\ \mbox{Charlson Comorbidity Indexb N (%) & & & & & & & & & & & & & & & & & & &$	Paroxysmal atrial fibrillation	4 (13)	3 (13)	1 (12)	0.73
$\begin{array}{c c} \mbox{Chronic kidney disease} & 3 (10) & 1 (4) & 2 (25) & 0.16 \\ \mbox{Chronic obstructive pulmonary disease} & 1 (3) & 1 (4) & 0 (0) & 0.74 \\ \mbox{Smoking} & & & & & & & & & & & & & & & & & & &$	Cerebrovascular disease	7 (23)	7 (30)	O (O)	0.09
Chronic obstructive pulmonary disease 1 (3) 1 (4) 0 (0) 0.74 Smoking -	Chronic kidney disease	3 (10)	1 (4)	2 (25)	0.16
Smoking 7 (23) 5 (22) 2 (25) 0.45 Past smoker 3 (10) 2 (9) 1 (12) 0.45 Recent glycosylated hemoglobin, mean (± SD) 8.8 (± 2) 8.8 (± 2) 9.0 (± 2) 0.72 Charlson Comorbidity Index ^b N (%) - - 0.88 - 0.90 (± 2) 0.72 0-3 6 (19) 5 (24) 1 (10) - 0.86 - 0.86 - 0.86 - 0.86 - 0.86 - 0.86 - 0.72 0.72 0.72 0.72 0.72 0.72 0.72 0.86 - 0.86 - 0.86 - 0.86 - 0.86 - 0.86 - 0.86 - 0.86 - 0.86 - 0.86 - 0.86 - 0.86 - 0.86 - 0.86 - 0.86 - 0.86 - 0.86 - 0.96 - 0.86 - 0.96 0.96 - 0.96 </td <td>Chronic obstructive pulmonary disease</td> <td>1 (3)</td> <td>1 (4)</td> <td>O (O)</td> <td>0.74</td>	Chronic obstructive pulmonary disease	1 (3)	1 (4)	O (O)	0.74
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Smoking				
$\begin{array}{c cccc} Past smoker & 3 (10) & 2 (9) & 1 (12) & 0.45 \\ Recent glycosylated hemoglobin, mean (\pm SD) & 8.8 (\pm 2) & 8.8 (\pm 2) & 9.0 (\pm 2) & 0.72 \\ Charlson Comorbidity Indexb N (%) & & & & & & & & & & & & & & & & & & &$	Smoker	7 (23)	5 (22)	2 (25)	0.45
$\begin{array}{c cccc} \mbox{Recent glycosylated hemoglobin, mean (\pm SD)} & 8.8 (\pm 2) & 8.8 (\pm 2) & 9.0 (\pm 2) & 0.72 \\ \mbox{Charlson Comorbidity Index^b N (\%)} & & & & & & & & & & & & & & & & & & &$	Past smoker	3 (10)	2 (9)	1 (12)	0.45
	Recent glycosylated hemoglobin, mean (± SD)	8.8 (±2)	8.8 (±2)	9.0 (±2)	0.72
	Charlson Comorbidity Index ^b N (%)				0.86
4-5 6 (19) 4 (17) 2 (25) >6 19 (61) 12 (52) 7 (88) Outcomes measured 10 (± 9) 0.31 Hospitalization duration, mean (± SD) 14 (± 11) 15 (± 12) 10 (± 9) 0.31 Days of antibiotic therapy, mean (± SD) 13 (± 11) 13 (± 11) 14 (± 14) 0.54	0-3	6 (19)	5 (24)	1 (10)	
>6 19 (61) 12 (52) 7 (88) Outcomes measured Hospitalization duration, mean (± SD) 14 (± 11) 15 (± 12) 10 (± 9) 0.31 Days of antibiotic therapy, mean (± SD) 13 (± 11) 13 (± 11) 14 (± 14) 0.54	4-5	6 (19)	4 (17)	2 (25)	
Outcomes measured 14 (± 11) 15 (± 12) 10 (± 9) 0.31 Days of antibiotic therapy, mean (± SD) 13 (± 11) 13 (± 11) 14 (± 14) 0.54	>6	19 (61)	12 (52)	7 (88)	
Hospitalization duration, mean (\pm SD)14 (\pm 11)15 (\pm 12)10 (\pm 9)0.31Days of antibiotic therapy, mean (\pm SD)13 (\pm 11)13 (\pm 11)14 (\pm 14)0.54	Outcomes measured	· · /			
Days of antibiotic therapy, mean (\pm SD) 13 (\pm 11) 13 (\pm 11) 14 (\pm 14) 0.54	Hospitalization duration, mean (± SD)	$14(\pm 11)$	15 (± 12)	10 (± 9)	0.31
	Days of antibiotic therapy, mean (± SD)	13 (± 11)	13 (± 11)	14 (± 14)	0.54
Rec admission N (%) 8 (26) 6 (26) 2 (25) 0.95	Rec admission N (%)	8 (26)	6 (26)	2 (25)	0.95

^aPeripheral vascular assessments are provided in Table S1 in the Supplementary Materials.

^bCharlson Comorbidity Index score: 0-3 = 77%-98% 10-year survival rate, 4-5 = 21-53% and >6 = 0-2%.

hospitalization or within 90 days of discharge. There were no differences in co-morbidities, Charlson Comorbidity Index, LOS and recurrent admissions between patients who underwent amputation (N=23) and those who were treated conservatively (N=8, **Table 1**).

Microbial Data Analysis

Biopsies were obtained within a median of 3 (IQR 1-4) days from admission. Antibiotic treatment was given for a median of one day (IQR 0-2) before biopsy collection. Bacteria were isolated in 30 culture samples (97%). All 31 DNA samples were sequenced successfully using 16S rRNA and metagenomic sequencing. Thirty 16S rRNA samples and 13 metagenomic samples were defined as high quality and included in the analysis.

Culture results: Thirty-two different bacteria were identified across patients with a mean of four bacteria per ulcer; there were no differences in mean bacterial number in culture-based results between patients who were conservatively treated and those who underwent amputation (Table 2). Gram-negative bacteria (GNB) and facultative anaerobes were the most prevalent (51% and 64%, respectively, Figure 2A, B). Streptococcus, Staphylococcus, Proteus, Enterococcus and Bacteroides were the five most dominant genera (Figure 3A), while Staphylococcus aureus, Enterococcus fecalis, Morganella morganii, Proteus mirabilis and Pseudomonas aeruginosa were the five most dominant species (Figure 3B). Notably, Staphylococcus aureus was more prevalent among patients who were treated conservatively (63% vs. 23%, p=0.048, Table 2). Bacteria with AMP-C β -lactamase resistance mechanism were more prevalent in patients who underwent amputation (39% vs. 0, p=0.04, Table 2). All other recognized resistance mechanisms were distributed similarly among the patients.

16S rRNA sequencing results: A mean of 27 genera per sample were identified with predominance of anaerobes and GNB (56% and 61% respectively, **Figures 2A, B**). *Prevotella*, *Porphyromonas, Bacteroides, Streptococcus* and *Morganella* were the five most prevalent genera (**Figure 3C**). Mean relative abundances of the most abundant bacteria are demonstrated in **Figure S1A** in the **Supplementary Materials**. No associations between specific genera and clinical outcomes were found.

Metagenomic results: A mean of 26 species per sample were demonstrated (Table 2). GNB and anaerobes predominated (79% and 76% respectively, Figures 2C, D). The five most prevalent species were Prevotella intermedia, Bacteroides fragilis, Prevotella melaninogenica, Prevotella scopos and Porphyromonas asaccharolytica (Figure 3E). Mean relative abundances of the most abundant bacteria are demonstrated in Figures S1B, C in the Supplementary Materials. Bacteroides genus was more common among patients who underwent amputation compared with those who were treated conservatively (p<0.001, Figure 4). Species level analysis showed that Bacteroides fragilis and Bacteroides xylanisolvens predominated IDFU of patients who underwent amputation (p=0.04, p=0.002, respectively, Figure 4), while Proteus mirabilis, Pseudomonas aeruginosa, Streptococcus agalactiae and Escherichia coli were more prevalent among patients who

were treated conservatively (p=0.02, p<0.001, p=0.002, p=0.04, respectively, **Figure S2**).

Comparison between investigative tools: 16S rRNA sequencing recognized 85% of the genera and metagenomic sequencing recognized all the species isolated in cultures. Overall, GNB were more prevalent than Gram-positive bacteria; this was most pronounced in the sequenced data. Anaerobes predominated in 16S rRNA and metagenomic sequencing compared to culture results (**Figure 2**).

Ulcer size: Culture results did not reveal any significant association between specific genera or species and ulcer size. However, certain bacteria correlated with ulcer size in sequenced data results; *Staphylococcus*, *Prevotella* and *Bilophila* genera were more common in ulcers <3 cm, compared with ulcers 3-10 cm, according to 16S rRNA sequencing (p<0.001, **Figure 5**). Metagenomics provided more in-depth characterization, revealing 12 species that were more prevalent in small ulcers and 21 species in larger ulcers (**Table S3** and **Figures S3**, **S4**). We did not find correlations between ulcer size and clinical outcomes (**Table 1**).

Functional Data Analysis

Bacterial functional genes were sequenced and analyzed. A cluster of five samples of patients who underwent amputation was found; 220 pathway genes were more prevalent in these five IDFU compared to other samples. Among them were resistance genes for beta-lactam and vancomycin (p<0.001), Pseudomonas aeruginosa, Escherichia coli and Vibrio-cholera biofilm formation genes (p<0.001) and genes associated with bacterial virulence factors (**Figure 6A** and **Table S4A**). Moreover, these patients had more peripheral vascular disease compared to other patients (p=0.003), and their IDFU yielded more cultured bacteria with AMP-C β -lactamase resistant mechanism (p=0.017).

Furthermore, analysis of associations between each functional gene and clinical outcomes revealed genes that were more prevalent in patients who underwent amputation. These included, among others, resistance genes for vancomycin, genes related to biofilm production and other genes related to virulence factors (p<0.001, **Figure 6B** and **Table S4B**).

DISCUSSION

This study explored the bacterial bioburden of IDFU and its association with clinical outcomes, in hospitalized patients. We based our results on biopsies, which are considered more reliable than swab sampling (Pellizzer et al., 2001; Lipsky et al., 2012; Rhoads et al., 2012a; Lipsky et al., 2020) and used three investigative tools: cultures, 16S rRNA sequencing and metagenomic sequencing. Our main findings were fivefold:

Anaerobes and GNB Dominate IDFU

IDFU are considered a diverse, polymicrobial ecosystem with very heterogenous bacterial communities (Smith et al., 2016; Hitam et al., 2019). The bacterial bioburden of all 31 IDFU was indeed varied; however, we found shared general characteristics.

TABLE 2 | Overview of traditional cultures, 16S rRNA sequencing and metagenomic sequencing results.

	Total (N=31)	Amputation (N=23)	Conservative treatment (N=8)	P-value
Culture results				
Patients with positive culture results, N (%)	30 (97)	22 (96)	8 (100)	0.79
Number of bacteria per patient, mean (± SD)	4.0 (± 1.8)	4.4 (±2.7)	3.8 (±1.5)	0.45
Gram stain, mean (± SD)				
Gram-positive bacteria	1.9 (± 1.2)	1.8 (±1.1)	2.2 (±1.6)	0.37
Gram-negative bacteria	2.2 (± 1.4)	2.3 (±1.3)	1.9 (± 1.8)	0.52
Oxygen requirements, mean (± SD)				
Aerobic bacteria	0.6 (±0.7)	0.7 (±0.7)	0.5 (±0.5)	0.48
Anaerobic bacteria	0.7 (±0.9)	0.6 (±0.6)	$1.0(\pm 1.4)$	0.35
Facultative anaerobic bacteria	2.7 (± 1.6)	2.7 (± 1.6)	2.6 (±1.8)	0.92
5 most prevalent species – occurrences, N (%)				
Staphylococcus aureus	10 (33)	5 (23)	5 (63)	0.048
Enterococcus fecalis	9 (30)	7 (32)	2 (25)	0.57
Morganella morganii	8 (26)	6 (27)	2(25)	0.14
Proteus mirabilis	7 (23)	3 (14)	4 (50)	0.053
Pseudomonas aeruginosa	6 (20)	5 (23)	1 (12)	0.50
Resistance mechanisms, N (%)		- (-)		
Any resistance	13 (43)	11 (50)	2 (25)	0.24
AMP-C	9 (30)	9 (41)	O (O)	0.041
ESBL	1 (3)	1 (4)	0 (0)	0.74
MRSA	3 (10)	2 (9)	1 (12)	0.60
Pseudomonas aeruginosa MDR	1 (3)	1 (4)	0 (0)	0.74
Carbapenem resistant Enterobacteriaceae	2 (7)	1 (4)	1 (12)	0.46
16s rRNA sequencing results	- (•)		. ()	
Patients with high quality results N (%)	30 (97)	22 (96)	8 (100)	0.79
Number of genera per patient* mean (+ SD)	26.9 (+12.9)	28.5 (+ 11.8)	22(+12)	0.19
Gram stain, mean (+ SD)	2010 (2 1210)	2010 (2 1 110)	(- ·-)	0110
Gram-positive bacteria	10.7(+5.3)	11.4(+5.3)	85(+53)	0.20
Gram-negative bacteria	16.2(+7.4)	$17.0(\pm 7.5)$	13.9(+7.1)	0.30
Oxygen requirements mean (+ SD)	1012 (2 111)			0.000
Aerobic bacteria	51(+50)	51(+50)	51(+50)	0.99
Anaerobic bacteria	151(+87)	164(+84)	11 4 (+ 8 7)	0.00
Facultative anaerobic bacteria, mean	6.7 (+ 3.2)	7.0(+3.1)	5.9(+3.1)	0.47
5 most prevalent genera – occurrences. N (%)	··· (_ ··-)			
Prevotella	28 (93)	21 (70)	7 (23)	
Prophyromonas	22 (73)	18 (60)	4 (13)	
Bacteroides	21 (70)	19 (63)	2 (7)	
Streptococcus	20 (67)	14 (47)	6 (20)	
Morganella	18 (60)	14 (47)	4 (13)	
Metagenomics sequencing results	10 (00)		1 (10)	
Patients with high quality results N (%)	13 (42)	10 (43)	3 (37)	0.80
Number of species ^a mean $(+ SD)$	26.1 (7.9)	26.8 (7.6)	23.7 (10.0)	0.47
Gram stain mean (+ SD)	2011 (110)	2010 (110)	2011 (1010)	0
Gram-positive bacteria	54(31)	5 2 (3 5)	60(17)	0.81
Gram-pegative bacteria	20.6 (8.1)	21 5 (7 9)	17.7 (9.6)	0.47
Oxygen requirements mean (+ SD)	20.0 (0.1)	21.0 (1.0)	(1.0)	0.47
Aerobic bacteria	15(10)	15(12)	1.3 (0.6)	0.94
Anaerobic bacteria	19.8 (6.8)	20.8 (6.2)	16.3 (9.0)	0.34
Facultative anaerobic bacteria	15.0 (0.0)	4 1 (2 1)	5.7 (3.2)	0.01
5 most prevalent species – occurrence $N(%)$	4.0 (2.4)	4.1 (2.1)	3.7 (3.2)	0.23
Prevotella intermedia	13 (100)	10 (77)	3 (23)	
Ractaroides fracilis	11 (95)	Q (60)	2 (16)	
Prevotella melaninogenica	10 (77)	9 (09) 8 (61)	2 (10)	
Provotella soopos		7 (59)	2 (10)	
Frevuleria Scopus	9 (09) 9 (61)	7 (53)	∠ (10) 1 (0)	
F บายาญายาทยาลร สรสบบาสิ101ytilica	0 (10)	(00)	I (O)	

^aTaxonomic data were subsequently filtered by a minimum of 0.1% relative abundance and detection in at least 3 samples.

First, 56% of bacteria identified in 16S rRNA sequencing and 76% in metagenomics were anaerobes. Anaerobes are considered commensals, relatively nonvirulent bacteria in immunocompetent patients, predominantly seen in deeper and more chronic wounds (Charles et al., 2015). The dominance of anaerobes in DFU was previously demonstrated in studies using molecular tools (Dowd et al., 2008), presumably secondary to microvascular lower limb ischemia. Their dominance in sequenced data emphasized the disadvantage of culture-based results, as less sensitive to anaerobes, and highlights the importance of molecular methods to improve our understanding of the true microbiome of IDFU. Second, GNB



FIGURE 2 | (A–D). Comparison of Gram staining characteristics and oxygen requirements of isolated and sequenced bacteria as reflected by traditional cultures, 16S rRNA and metagenomic sequencing. Numbers represent percentages (%); (A, B) Traditional cultures vs. 16S rRNA sequencing results (N=30): Gram staining, p=0.07; oxygen requirements (anaerobes and facultative anaerobes, p<0.001). (C, D) Traditional cultures, 16S rRNA sequencing and metagenomic sequencing results (N=13): Gram staining, p=0.01; oxygen requirements (anaerobes, p<0.001; facultative anaerobes, p=0.001).

were more common than Gram-positive in all three methods. This finding strengthens the emerging body of data regarding the high prevalence of GNB in DFU, mainly in warmer countries around Asia and Africa (Al Benwan et al., 2012; Dunyach-Remy et al., 2016). In a study conducted in Pakistan on 473 specimens, 76% of the IDFU cultured had high abundance of GNB (Miyan et al., 2017). Data regarding the principal involvement of anaerobic and GNB in IDFU, based on sequenced results, can improve antibiotics suitability, and challenge the current common practice of de-escalating empiric antibiotic treatment based on culture results only (Lipsky et al., 2012; Lipsky et al., 2020).

The Association Between Specific Genera/ Species and Clinical Outcomes

As expected, *Staphylococcus aureus* was the most common pathogen isolated by cultures, yet this well-known cause of skin, soft tissue, and bone infections was less dominant in sequencing results. *Staphylococcus aureus* is known to be a relatively virulent pathogen associated with adverse clinical outcomes of DFU (Citron et al., 2007; Kalan et al., 2019). Unexpectedly, in this cohort, it was associated with 63% of conservatively treated IDFU vs. 23% of patients who underwent amputation (p=0.048). Furthermore, and counterintuitively, *the Staphylococcus* genus was related to small ulcers according to 16S rRNA results (<3cm, p<0.001). We assume that this finding might be explained by the fact that as the wound deepens, the *Staphylococcus* genus is masked by anaerobes which thrive in anaerobic environments. This accords with a 16S rRNA sequencing study that showed that superficial and short-duration ulcers were associated with relatively higher abundance of *Staphylococcus* compared to deep DFU (Gardner et al., 2013). Additionally, we believe that patients with more severe and chronic wounds were exposed to antibiotics directed against *Staphylococcus aureus*; therefore, it was less dominant in these ulcers.

Metagenomic results suggested a possible link between specific genera, species, and clinical outcomes. *Bacteroides* genus (specifically *bacteroides fragilis* and *xylanisolvens* species) were more prevalent in patients who underwent amputation (p=0.001). *Bacteroides fragilis* was described as a relatively common pathogen in IDFU (El-Tahawy, 2000; Abdulrazak et al., 2005; Citron et al., 2007). However, its connection to adverse clinical outcomes is less recognized. On the other hand, *Proteus mirabilis, Pseudomonas aeruginosa, Streptococcus agalactiae* and *Escherichia coli* were more prevalent among conservatively treated patients. To the best of our knowledge, these correlations have not been described previously. Limited by a relatively small sample size, we can only note that these bacteria may influence clinical outcomes. Further studies are needed to establish the role of these bacteria in wound healing.

Ulcer Size Might Influence the IDFU Microbiome

Although higher risk for amputation was previously described in patients with large ulcers (Oyibo et al., 2001), we did not find correlations between ulcer size and clinical outcomes. However, our results suggest that ulcer size might affect the IDFU



ecosystem. *Staphylococcus*, *Prevotella* and *Bilophila* genera were associated with ulcers smaller than 3 cm as reflected by 16S rRNA sequencing, as well as 11 additional species according to metagenomics. We also found 19 species that were more prevalent in larger ulcers, noted in **Table S3**. Few studies investigated the impact of ulcer size on the ulcer microbiome. One stated that deeper ulcers contain higher levels of anaerobes and have more diverse microbiota (Gardner et al., 2013). These findings require additional investigation to solve a "chicken and egg" situation – does ulcer size influence the microbiome or do certain bacteria cause the IDFU to increase?

Resistance Mechanisms and Bacterial Virulence Factor Genes Associated With Adverse Clinical Outcomes

Among the cultured bacteria, 43% exhibited at least one wellknown resistance mechanism (MRSA, AMP-C beta-lactamase, Extended spectrum beta-lactamase [ESBL] and multi-drug resistant GNB). We found that bacteria with AMP-C betalactamase resistance mechanism were more prevalent in patients who underwent amputation (41% vs. 30%, p=0.041); however, all other resistance mechanisms were distributed similarly among all 31 patients, whether amputated or not. Traditionally, bacterial resistance profiling based on cultures, provide limited and mostly phenotypic data; metagenomic data provide insights into the pathogenicity of the bacteria by detecting functional genes, some related to antibiotic resistance mechanisms, biofilm formation and virulence factors.

In this study, the functional metagenomics data revealed genes related to beta-lactam and vancomycin resistance pathways. Other genes related to antimicrobial resistance were found and were more common in patients who underwent amputation, however with no relation to specific antibiotic agent. The widespread presence of resistant bacteria in DFU was noted (Saltoglu et al., 2018); however, only a handful of studies used metagenomic approaches to evaluate the IDFU resistome related to clinical outcomes (Kallstrom, 2014). Recent research efforts attempted to characterize this



FIGURE 4 | Association between *Bacteroides* genus and amputation according to 16S rRNA sequencing and metagenomic sequencing. p<0.001; *Bacteroides fragilis*, p=0.04; *Bacteroides xylanisolvens*, p=0.002.

impact; a meta-transcriptomic study used RNA sequencing to identify 132 functional pathway genes in 16 IDFU samples; some of which were associated with infection severity (Zakrzewski et al., 2020). In our cohort, vancomycin resistance

genes were more common in patients with wounds that required amputation (Figure 6B).

Additionally, genes associated with bacterial virulence factors other than resistance mechanisms were correlated with IDFU







FIGURE 6 | (A, B). Analysis of functional genes. Yellow stars indicate genes related to bacterial virulence factors. (A) A cluster of five samples of patients with IDFU who underwent amputation. These patients had more severe peripheral vascular disease compared to other patients, p=0.003. (B) Functional genes differentiating patients who underwent amputation from patients who were treated conservatively.

that resulted in amputation; some were associated with biofilm production, quorum sensing and toxin producing. Given the relatively limited sample size, additional research is needed to establish the implications of these genes.

Peripheral Vascular Disease Might Influence the IDFU Microbiome

While searching for clusters with shared genes and possible impact on clinical outcomes, a cluster of five patients who underwent amputation was found. These patients demonstrated unique, common pathway genes. In comparison, they shared more genes associated with bacterial virulence factors such as beta-lactam and vancomycin resistance, and pseudomonas aeruginosa and vibrio-cholera biofilm-forming genes (p<0.001, Figure 6A). More of these patients had peripheral vascular disease compared to others and their IDFU cultures grew more AMP-C resistant bacteria. PVD was previously associated with the tendency to develop unhealing ulcers in diabetic patients (Lipsky et al., 2006; Lavery et al., 2017; Shin et al., 2017; Lu et al., 2021); however, data regarding the microbiome of ulcers in patients with PVD are lacking. The decreased blood flow characterizing patients with PVD promotes poor wound healing. This may give an advantage to specific bacteria, mostly anaerobes, which impact clinical outcomes.

This study had several limitations. First, metagenomic analysis of tissue samples is considerably challenging. Unlike 16S rRNA sequencing, metagenomic sequencing does not include a PCR amplification step. Therefore, all available genomic material is sequenced. As the tissue samples consist primarily of human DNA, the likelihood of sequencing microbial DNA is decreased. Therefore, we decided to include only highquality samples that could reliably describe the bacterial profile of the ulcer; a decision that led to limited sample size in the metagenomic analysis. Larger scale investigations are needed to validate our results. Second, deep tissue biopsies could only be taken by skilled, attending orthopedic surgeons sometimes after antibiotic therapy was initiated. Since biopsies are more reliable compared to swab-based sampling, we chose to make this methodological compromise. Furthermore, recent studies showed that antibiotic therapy does not shift the microbiome in a way that affects its composition or outcomes (Kalan et al., 2018). Accordingly, we assume that since biopsies were taken a median of one day after initiation of antibiotic therapy, this did not have much influence on the sequenced bacterial DNA. Culture samples were obtained before antibiotic initiation. Finally, we did not compare IDFU samples to normal skin samples or to samples obtained from uninfected DFU as controls. Since we based our results on deep tissue biopsies, sampling healthy skin or uninfected ulcers did not seem justified.

CONCLUSION

Molecular sequencing tools improve our knowledge of the complex microbial biodiversity of IDFU and emphasize the high prevalence of anaerobes and GNB in these ulcers. Sequencing results highlight possible associations among certain genera and species to clinical outcomes, such as associations between *Bacteroides* genus and amputation and between *Staphylococcus aureus* and smaller ulcers. Metagenomic analysis additionally reveals associations between functional genes related to bacterial virulence factors and amputation. Our study demonstrates the importance of investigating the microbiome of IDFU and its potential in improving treatment strategies.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are publicly available. This data can be found here: National Center for Biotechnology Information (NCBI) BioProject database under accession number PRJNA741238.

ETHICS STATEMENT

The study was performed in accordance with the declaration of Helsinki and was approved by the Institutional Ethics Committee of Meir Medical Center (0143-18MMC). Patients provided signed informed consent. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

Conception and design of study: MC, HM-Z, NG-Z, SC, and MK. Acquisition of data: HM-Z, AZ, YC, and YP. Analysis and interpretation of data: MC, SC, HM-Z, NG-Z, and TG. Drafting the manuscript: HM-Z. Revising the manuscript critically for important intellectual content: MC, NG-Z, and SC. Approval of the version of the manuscript to be published: HM-Z, SC, TG, AZ, MK, YC, YP, NG-Z, and MC. MC, HM-Z, NG-Z, and SC are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

FUNDING

This work was supported by the Technion Institute of Technology, "Keren Hanasi", Cathedra, the Technion Integrated Cancer Center, the Alon Fellowship for Outstanding Young Researchers, the Israeli Science Foundation (grant 1571/17), the Seerave Foundation, the German-Israeli Foundation for Scientific Research and Development (grant I-1076-416.6-20), the Canadian Institute for Advanced Research (Azrieli Global Scholars; grant FL-000969), the Israel Cancer Research Fund (grant 1016142), Human Frontier Science Program Career Development Award (grant CDA00025/ 2019-C), and the Gutwirth foundation award. NG-Z is a CIFAR Fellow in the Humans & the Microbiome Program and a Horev Fellow (Taub Foundation). The Applebaum family foundation #11916.

ACKNOWLEDGMENTS

We thank the NG-Z lab for discussions and help, Eitan Sharon, PhD for advice regarding the molecular data analysis, and Stefan Green, PhD, George Chlipala, phD and Kevin Kunstman for help in sequencing. We would also like to thank Itan Savir, DPM and

REFERENCES

- Abdulrazak, A., Bitar, Z. I., Al-Shamali, A. A., and Mobasher, L. A. (2005). Bacteriological Study of Diabetic Foot Infections. *J. Diabetes Its Complicat.* 19, 138–141. doi: 10.1016/j.jdiacomp.2004.06.001
- Al Benwan, K., Al Mulla, A., and Rotimi, V. O. (2012). A Study of the Microbiology of Diabetic Foot Infections in a Teaching Hospital in Kuwait. J. Infect. Public Health 5, 1–8. doi: 10.1016/j.jiph.2011.07.004
- Armstrong, D. G., Lavery, L. A., and Harkless, L. B. (1998). Validation of a Diabetic Wound Classification System. The Contribution of Depth, Infection, and Ischemia to Risk of Amputation. *Diabetes Care* 21, 855–859. doi: 10.2337/ diacare.21.5.855
- Boulton, A. J. M., Vileikyte, L., Ragnarson-Tennvall, G., and Apelqvist, J. (2005). The Global Burden of Diabetic Foot Disease. *Lancet* 366, 1719–1724. doi: 10.1016/S0140-6736(05)67698-2
- Charles, P. G. P., Uçkay, I., Kressmann, B., Emonet, S., and Lipsky, B. A. (2015). The Role of Anaerobes in Diabetic Foot Infections. *Anaerobe* 34, 8. doi: 10.1016/j.anaerobe.2015.03.009
- Citron, D. M., Goldstein, E. J., Merriam, C. V., Lipsky, B. A., and Abramson, M. A. (2007). Bacteriology of Moderate-to-Severe Diabetic Foot Infections and *In Vitro* Activity of Antimicrobial Agents. *J. Clin. Microbiol.* 45, 2819–2828. doi: 10.1128/JCM.00551-07
- Dowd, S. E., Sun, Y., Secor, P. R., Rhoads, D. D., Wolcott, B. M., James, G. A., et al. (2008). Survey of Bacterial Diversity in Chronic Wounds Using Pyrosequencing, DGGE, and Full Ribosome Shotgun Sequencing. BMC Microbiol. 8, 43. doi: 10.1186/1471-2180-8-43
- Dowd, S. E., Wolcott, R. D., Sun, Y., McKeehan, T., Smith, E., and Rhoads, D. (2008). Polymicrobial Nature of Chronic Diabetic Foot Ulcer Biofilm Infections Determined Using Bacterial Tag Encoded FLX Amplicon Pyrosequencing (bTEFAP). *PLoS One* 3 (10), e3326. doi: 10.1371/ journal.pone.0003326
- Dunyach-Remy, C., Ngba Essebe, C., Sotto, A., and Lavigne, J. P. (2016). Staphylococcus Aureus Toxins and Diabetic Foot Ulcers: Role in Pathogenesis and Interest in Diagnosis. *Toxins (Basel)* 8 (7), 209. doi: 10.3390/toxins8070209
- El-Tahawy, A. (2000). Bacteriology of Diabetic Foot. Saudi Med. J. 21, 344-347.
- Gardner, S. E., Haleem, A., Jao, Y. L., Hillis, S. L., Femino, J. E., Phisitkul, P., et al. (2014). Cultures of Diabetic Foot Ulcers Without Clinical Signs of Infection do Not Predict Outcomes. *Diabetes Care* 37, 10:2693–2701. doi: 10.2337/dc14-0051
- Gardner, S. E., Hillis, S. L., Heilmann, K., Segre, J. A., and Grice, E. A. (2013). The Neuropathic Diabetic Foot Ulcer Microbiome is Associated With Clinical Factors. *Diabetes* 62, 923. doi: 10.2337/db12-0771
- Hitam, S., Hassan, S. A., and Maning, N. (2019). The Significant Association Between Polymicrobial Diabetic Foot Infection and its Severity and Outcomes. *Malaysian J. Med. Sci.* 2, 1:107–1:114. doi: 10.21315/mjms2019.26.1.10
- Hunt, J. A. (1992). Foot Infections in Diabetes are Rarely Due to a Single Microorganism. Diabetes Med. J. Br. Diabetes Assoc. 9, 749-752. doi: 10.1111/j.1464-5491.1992.tb01885
- Kalan, L., Meisel, J. S., Loesche, M. A., Horwinski, J., Soaita, I., Chen, X., et al. (2018). The Microbial Basis of Impaired Wound Healing: Differential Roles for Pathogens, "Bystanders", and Strain-Level Diversification in Clinical Outcomes. *bioRxiv*, 427567. doi: 10.1101/427567

Dror Ben-David, MD from the Department of Orthopedics B, Meir Medical Center, Kfar Saba, Israel for their assistance with biopsies collection and to Faye Schreiber for editorial assistance.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcimb.2022.836699/full#supplementary-material

- Kalan, L. R., Meisel, J. S., Loesche, M. A., Horwinski, J., Soaita, L., Chen, X., et al. (2019). Strain and Species Level Variations in the Microbiome of Diabetic Wounds is Associated With Clinical Outcomes and Therapeutic Efficacy. *Cell Host Microbe* 25, 641–655. doi: 10.1016/j.chom.2019.03.006
- Kallstrom, G. (2014). Are Quantitative Bacterial Wound Cultures Useful? J. Clin. Microbiol. 52, 8:2753–8:2756. doi: 10.1128/JCM.00522-14
- Lavery, L. A., Armstrong, D. G., and Harkless, L. B. (1996). Classification of Diabetic Foot Wounds. J. Foot Ankle Surg. 35, 528–531. doi: 10.1016/S1067-2516(96)80125-6
- Lavery, L. A., Armstrong, D. G., Murdoch, D. P., Peters, E. J. P., and Lipsky, B. A. (2017). Validation of the Infectious Diseases Society of America's Diabetic Foot Infection Classification System. *Clin. Infect. Dis.* 44, 562–565. doi: 10.1086/511036
- Lavery, L. A., Armstrong, D. G., Wunderlich, R. P., Mohler, M. J., Wendel, C. S., and Lipsky, B. A. (2006). Risk Factors for Foot Infections in Persons With Diabetes Mellitus. *Diabetes Care* 29, 1288–1293. doi: 10.2337/dc05-2425
- Lipsky, B. A., Aragón-Sánchez, J., Diggle, M., Embil, J., Kono, S., Lavery, L., et al. (2016). IWGDF Guidance on the Diagnosis and Management of Foot Infections in Persons With Diabetes. *Diabetes Metab. Res. Rev.* 32, 45–74. doi: 10.1002/dmrr.2699
- Lipsky, B. A., Armstrong, D. G., Citron, D. M., Tice, A. D., Morgenstern, D. E., and Abramson, M. A. (2005). Ertapenem Versus Piperacil-Lin/Tazobactam for Diabetic Foot Infections (SIDESTEP): Prospective, Randomised, Controlled, Double-Blinded, Multicentre Trial. *Lancet* 366, 1695–1703. doi: 10.1016/ S0140-6736(05)67694-5
- Lipsky, B. A., Berendt, A. R., Cornia, P. B., Pile, J. C., Peters, E. J., Armstrong, D. G., et al. (2012). 2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections. *Clin. Infect. Dis.* 54, e132–e173. doi: 10.1093/cid/cis346
- Lipsky, B. A., Berendt, A. R., Deery, H. G., Embil, J. M., Joseph, W. S., Karchmer, A. W., et al. (2006). Infectious Diseases Society of America. Diagnosis and Treatment of Diabetic Foot Infections. *Plast. Reconstr. Surg.* 117, 212S–238S. doi: 10.1097/01.prs.0000222737.09322.77
- Lipsky, B. A., Senneville, É, Abbas, Z. G., et al. (2020). Guidelines on the Diagnosis and Treatment of Foot Infection in Persons With Diabetes (IWGDF 2019 Update). Diabetes Metab. Res. Rev. 36 (S1), 1–24. doi: 10.1002/dmrr.3280
- Lu, Q., Wang, J., Wei, X., Wang, G., and Xu, Y. (2021). Risk Factors for Major Amputation in Diabetic Foot Ulcer Patients. *Diabetes Metab. Syndr. Obes.* 14, 2019–2027. doi: 10.2147/DMSO.S307815
- Miyan, Z., Fawwad, A., Sabir, R., and Basit, A. (2017). Microbiological Pattern of Diabetic Foot Infections at a Tertiary Care Center in a Developing Country. J. Pak Med. Assoc. 67 (5), 665–669.
- Oyibo, S. O., Jude, E. B., Tarawneh, I., Nguyen, H. C., Armstrong, D. G., Harkless, L. B., et al. (2001). The Effects of Ulcer Size and Site, Patient's Age, Sex and Type and Duration of Diabetes on the Outcome of Diabetic Foot Ulcers. *Diabetes Med.* 18 (2), 133–138. doi: 10.1046/j.1464-5491.2001.00422.x
- Pellizzer, G., Strazzabosco, M., Presi, S., Furlan, F., Lora, L., Benedetti, P., et al. (2001). Deep Tissue Biopsy vs. Superficial Swab Culture Monitoring in the Microbiological Assessment of Limb-Threatening Diabetic Foot Infection. *Diabet. Med.* 18, 822–827. doi: 10.1046/j.1464-5491.2001.00584.x
- Rhoads, D. D., Cox, S. B., Rees, E. J., Sun, Y., and Wolcott, R. D. (2012a). Clinical Identification of Bacteria in Human Chronic Wound Infections: Culturing vs. 16S Ribosomal DNA Sequencing. *BMC Infect. Dis.* 12, 321. doi: 10.1186/1471-2334-12-321

- Rhoads, D. D., Wolcott, R. D., Sun, Y., and Dowd, S. E. (2012b). Comparison of Culture and Molecular Identification of Bacteria in Chronic Wounds. *Int. J. Mol. Sci.* 13, 2535–2550. doi: 10.3390/ijms13032535
- Saltoglu, N., Ergonul, O., Tulek, N., Yemisen, M., Kadanali, A., Karagoz, G., et al. (2018). Influence of Multidrug Resistant Organisms on the Outcome of Diabetic Foot Infection. *Int. J. Infect. Dis.* 70, 10–14. doi: 10.1016/j.ijid.2018.02.013
- Shin, J. Y., Roh, S. G., Sharaf, B., and Lee, N. H. (2017). Risk of Major Limb Amputation in Diabetic Foot Ulcer and Accompanying Disease: A Meta-Analysis. J. Plast. Reconstr. Aesthet. Surg. 70, 12:1681–1688. doi: 10.1016/ j.bjps.2017.07.015
- Smith, K., Collier, A., Townsend, E. M., O'Donnell, L. E., Bal, A. M., Butcher, J., et al. (2016). One Step Closer to Understanding the Role of Bacteria in Diabetic Foot Ulcers: Characterizing the Microbiome of Ulcers. *BMC Microbiol*. 16, 54. doi: 10.1186/s12866-016-0665-z
- Suryaletha, K., John, J., Radhakrishnan, M. P., George, S., and Thomas, S. (2018). Metataxonomic Approach to Decipher the Polymicrobial Burden in Diabetic Foot Ulcer and its Biofilm Mode of Infection. *Int. Wound J.* 15, 473–481. doi: 10.1111/iwj.12888
- Treece, K. A., Macfarlane, R. M., Pound, N., Game, F. L., and Jeffcoate, W. J. (2004). Validation of a System of Foot Ulcer Classification in Diabetes Mellitus. *Diabetes Med.* 21, 987–991. doi: 10.1111/j.1464-5491.2004.01275.x
- Van Asten, S. A. V., La Fontaine, J., Peters, E. J. G., Bhavan, K., Kim, P. J., and Lavery, L. A. (2016). The Microbiome of Diabetic Foot Osteomyelitis. *Eur. J. Clin. Microbiol. Infect. Dis.* 35, 293–298. doi: 10.1007/s10096-015-2544-1
- Volmer Thole, M., and Lobmann, R. (2016). Neuropathy and Diabetic Foot Syndrome. Int. J. Mol. Sci. 17, 6. doi: 10.3390/ijms17060917

- Wolcott, R. D., Hanson, J. D., Rees, E. J., Koenig, L. D., Phillips, C. D., and Wolcott, R. A. (2016). Analysis of the Chronic Wound Microbiota of 2,963 Patients by 16S rDNA Pyrosequencing. *Wound Repair Regener.* 24, 163–174. doi: 10.1111/ wrr.12370
- Zakrzewski, M., Vickery, K., Malone, M., and Hu, H. (2020). Metatranscriptomic Analysis Reveals Active Bacterial Communities in Diabetic Foot Infections. *Front. Microbiol.* 11. doi: 10.3389/fmicb.2020.01688

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Mudrik-Zohar, Carasso, Gefen, Zalmanovich, Katzir, Cohen, Paitan, Geva-Zatorsky and Chowers. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.